194 related articles for article (PubMed ID: 22539938)
1. Tetrastatin, the NC1 domain of the α4(IV) collagen chain: a novel potent anti-tumor matrikine.
Brassart-Pasco S; Sénéchal K; Thevenard J; Ramont L; Devy J; Di Stefano L; Dupont-Deshorgue A; Brézillon S; Feru J; Jazeron JF; Diebold MD; Ricard-Blum S; Maquart FX; Monboisse JC
PLoS One; 2012; 7(4):e29587. PubMed ID: 22539938
[TBL] [Abstract][Full Text] [Related]
2. Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo.
Roth JM; Akalu A; Zelmanovich A; Policarpio D; Ng B; MacDonald S; Formenti S; Liebes L; Brooks PC
Am J Pathol; 2005 Mar; 166(3):901-11. PubMed ID: 15743801
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis Inhibition by a Short 13 Amino Acid Peptide Sequence of Tetrastatin, the α4(IV) NC1 Domain of Collagen IV.
Vautrin-Glabik A; Devy J; Bour C; Baud S; Choulier L; Hoarau A; Dupont-Deshorgue A; Sellier C; Brassart B; Oudart JB; Ramont L; Monboisse JC; Brassart-Pasco S
Front Cell Dev Biol; 2020; 8():775. PubMed ID: 32850867
[TBL] [Abstract][Full Text] [Related]
4. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.
Boosani CS; Mannam AP; Cosgrove D; Silva R; Hodivala-Dilke KM; Keshamouni VG; Sudhakar A
Blood; 2007 Aug; 110(4):1168-77. PubMed ID: 17426256
[TBL] [Abstract][Full Text] [Related]
5. The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent.
Floquet N; Pasco S; Ramont L; Derreumaux P; Laronze JY; Nuzillard JM; Maquart FX; Alix AJ; Monboisse JC
J Biol Chem; 2004 Jan; 279(3):2091-100. PubMed ID: 14583633
[TBL] [Abstract][Full Text] [Related]
6. Conformation-dependent binding of a Tetrastatin peptide to α
Lambert E; Fuselier E; Ramont L; Brassart B; Dukic S; Oudart JB; Dupont-Deshorgue A; Sellier C; Machado C; Dauchez M; Monboisse JC; Maquart FX; Baud S; Brassart-Pasco S
Sci Rep; 2018 Jun; 8(1):9837. PubMed ID: 29959360
[TBL] [Abstract][Full Text] [Related]
7. Type IV collagen α1-chain noncollagenous domain blocks MMP-2 activation both in-vitro and in-vivo.
Sudhakar YA; Verma RK; Pawar SC
Sci Rep; 2014 Mar; 4():4136. PubMed ID: 24670518
[TBL] [Abstract][Full Text] [Related]
8. Quaternary organization of the goodpasture autoantigen, the alpha 3(IV) collagen chain. Sequestration of two cryptic autoepitopes by intrapromoter interactions with the alpha4 and alpha5 NC1 domains.
Borza DB; Bondar O; Todd P; Sundaramoorthy M; Sado Y; Ninomiya Y; Hudson BG
J Biol Chem; 2002 Oct; 277(42):40075-83. PubMed ID: 12193605
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific expression of the RGD-alpha3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice.
Miyoshi T; Hirohata S; Ogawa H; Doi M; Obika M; Yonezawa T; Sado Y; Kusachi S; Kyo S; Kondo S; Shiratori Y; Hudson BG; Ninomiya Y
FASEB J; 2006 Sep; 20(11):1904-6. PubMed ID: 16877525
[TBL] [Abstract][Full Text] [Related]
10. Type IV collagen of the glomerular basement membrane. Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains.
Boutaud A; Borza DB; Bondar O; Gunwar S; Netzer KO; Singh N; Ninomiya Y; Sado Y; Noelken ME; Hudson BG
J Biol Chem; 2000 Sep; 275(39):30716-24. PubMed ID: 10896941
[TBL] [Abstract][Full Text] [Related]
11. Distinct antitumor properties of a type IV collagen domain derived from basement membrane.
Maeshima Y; Colorado PC; Torre A; Holthaus KA; Grunkemeyer JA; Ericksen MB; Hopfer H; Xiao Y; Stillman IE; Kalluri R
J Biol Chem; 2000 Jul; 275(28):21340-8. PubMed ID: 10766752
[TBL] [Abstract][Full Text] [Related]
12. Recombinant alpha2(IV)NC1 domain of type IV collagen is an effective regulator of retinal capillary endothelial cell proliferation and inhibits pre-retinal neovascularisation.
Coleman G; Gardiner TA; Boutaud A; Stitt AW
Graefes Arch Clin Exp Ophthalmol; 2007 Apr; 245(4):581-7. PubMed ID: 16915401
[TBL] [Abstract][Full Text] [Related]
13. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin.
Sudhakar A; Nyberg P; Keshamouni VG; Mannam AP; Li J; Sugimoto H; Cosgrove D; Kalluri R
J Clin Invest; 2005 Oct; 115(10):2801-10. PubMed ID: 16151532
[TBL] [Abstract][Full Text] [Related]
14. Selective binding of integrins from different renal cell types to the NC1 domain of alpha3 and alpha1 chains of type IV collagen.
Aggeli AS; Kitsiou PV; Tzinia AK; Boutaud A; Hudson BG; Tsilibary EC
J Nephrol; 2009; 22(1):130-6. PubMed ID: 19229828
[TBL] [Abstract][Full Text] [Related]
15. Extra cellular matrix derived metabolite regulates angiogenesis by FasL mediated apoptosis.
Verma RK; Gunda V; Pawar SC; Sudhakar YA
PLoS One; 2013; 8(12):e80555. PubMed ID: 24324608
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of elastin peptide-mediated angiogenic signaling mechanism(s) in choroidal endothelial cells by the α6(IV)NC1 collagen fragment.
Gunda V; Verma RK; Sudhakar YA
Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):7828-35. PubMed ID: 24194191
[TBL] [Abstract][Full Text] [Related]
17. Cloning, purification, and characterization of a non-collagenous anti-angiogenic protein domain from human alpha1 type IV collagen expressed in Sf9 cells.
Boosani CS; Sudhakar A
Protein Expr Purif; 2006 Oct; 49(2):211-8. PubMed ID: 16631378
[TBL] [Abstract][Full Text] [Related]
18. In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model.
Pasco S; Ramont L; Venteo L; Pluot M; Maquart FX; Monboisse JC
Exp Cell Res; 2004 Dec; 301(2):251-65. PubMed ID: 15530861
[TBL] [Abstract][Full Text] [Related]
19. The NC1 domain of collagen IV encodes a novel network composed of the alpha 1, alpha 2, alpha 5, and alpha 6 chains in smooth muscle basement membranes.
Borza DB; Bondar O; Ninomiya Y; Sado Y; Naito I; Todd P; Hudson BG
J Biol Chem; 2001 Jul; 276(30):28532-40. PubMed ID: 11375996
[TBL] [Abstract][Full Text] [Related]
20. The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction.
Oudart JB; Doué M; Vautrin A; Brassart B; Sellier C; Dupont-Deshorgue A; Monboisse JC; Maquart FX; Brassart-Pasco S; Ramont L
Oncotarget; 2016 Jan; 7(2):1516-28. PubMed ID: 26621838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
